Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis

References

• Pelechas E, Kaltsonoudis E, Voulgari PV, et al. Rheumatoid arthritis. In: Pelechas E, editor. Illustrated handbook of rheumatic and musculo-skeletal diseases. Cham, Switzerland: Springer; 2019. p. 45–76.
   Google Scholar
• Tsirves GK, Voulgari PV, Pelechas E, et al. Cochlear involvement in patients with systemic autoimmune rheumatic diseases: a clinical and laboratory comparative study. Eur Arch Otorhinolaryngol. 2019;276(9):2419–2426.
   PubMed Web of Science ®Google Scholar
• Dadoun S, Zeboulon-Ktorza N, Combescure C, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine. 2013;80(1):29–33.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Convenvtional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. Rheumatol Int. 2019;39(8):1331–1341.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Radiological Findings of the cervical spine in rheumatoid arthritis: what a rheumatologist should know. Curr Rheumatol Rep. 2020;22(6):19.
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Pelechas E, Voulgari PV, et al. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int. 2020;40(8):1181–1191.
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130–136.
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182–188.
   PubMed Web of Science ®Google Scholar
• Storey GD. Alfred Baring Garrod (1819–1907). Rheumatology (Oxford). 2001;40(10):1189–1190.
   PubMed Web of Science ®Google Scholar
• Hench PS. Potential reversibility of rheumatoid arthritis. Ann Rheum Dis. 1949;8(2):90–96.
   PubMed Web of Science ®Google Scholar
• Hench PS. Reminiscences of the Nobel Festival, 1950. Proc Staff Meet Mayo Clin. 1951;26:424–437.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818–822.
   PubMed Web of Science ®Google Scholar
• Williams HJ, Willkens RF, Samuelson CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. J Rheumatol. 1984;11:760–763.
   PubMedGoogle Scholar
• Thompson RN, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol. 1984;11:760–763.
   PubMed Web of Science ®Google Scholar
• Andersen PA, West SG, O’Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med. 1985;103:489–496.
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Pelechas E, Voulgari PV, et al. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheu. 2019;48(4):597–602.
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Pelechas E, Voulgari PV, et al. Comment on: assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Rheumatology (Oxford). 2019;58(10):1883–1884.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Kaltsonoudis E, et al. Therapeutic options and cost-effectiveness for rheumatoid arthritis treatment. Curr Rheumatol Rep. 2020;22(8):44.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clin Rheumatol. 2020;39(4):1363–1368.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Rheumatoid arthritis treatment. A back to the drawing board project of high expectations for low unmet needs? J Clin Med. 2019;8(8):1237.
   Web of Science ®Google Scholar
• Epstein WV. Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience. Arthritis Rheum. 1996;39(11):1773–1780.
   PubMedGoogle Scholar
• Cohen S, Bigazzi PE, Commentary YT. Similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol. 1974;12(1):150–159.
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497.
   PubMed Web of Science ®Google Scholar
• Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229:869–871.
   PubMed Web of Science ®Google Scholar
• Humira® (adalimumab) prescribing information; [ cited 2020 Aug 24]. Available from: https://www.rxabbvie.com/pdf/humira/pdf
   Google Scholar
• Enbrel® (etanercept) prescribing information; [ cited 2020 Aug 24]. Available from: http://www.enbrel.com/documents/ENBREL-Prescribing-Information.pdf
   Google Scholar
• Remicade® (infliximab) prescribing information; [ cited 2020 Aug 24]. Available from: http://www.remicade.com/remicade/assets/HCP_PPI.pdf
   Google Scholar
• Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228(4705):1315–1317.
   PubMed Web of Science ®Google Scholar
• Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. MAbs. 2016;8(7):1177–1194.
   PubMed Web of Science ®Google Scholar
• Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2(1):52–62.
   PubMed Web of Science ®Google Scholar
• McCafferty J. The long and winding road to antibody therapeutics. MAbs. 2010;2(5):459–460.
   PubMed Web of Science ®Google Scholar
• Nixon AE, Sexton DJ, Ladner RC. Drugs derived from phage display. From candidate identification to clinical practice. mAbs. 2014;6(1):73–85.
   PubMed Web of Science ®Google Scholar
• Jespers LS, Roberts A, Mahler SM, et al. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology. 1994;12:899–903.
   PubMed Web of Science ®Google Scholar
• Kaymakçalan Z, Sakorafas P, Xiong L, et al. In vitro and in vivo comparison of adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, expressed in transfected CHO cells versus transgenic goats. Abstract 313. Clin Immunol. 2002;103(3):S1–S147.
   PubMed Web of Science ®Google Scholar
• Humira approval history; [ cited 2020 Aug 25]. Available from: https://www.drugs.com/history/humira.html
   Google Scholar
• Möller A, Emling F, Blohm D, et al. Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application. Cytokine. 1990;2(3):162–169.
   PubMedGoogle Scholar
• Keffer J, Probert L, Caziaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J. 1991;10(13):4025–4031.
   PubMed Web of Science ®Google Scholar
• Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7. Ann Rheum Dis. 1999;58(Suppl 1):I70–I72.
   PubMedGoogle Scholar
• Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety trial of adalimumab in rheumatoid arthritis). J Rheumatol. 2003;30(12):2563–2571.
   PubMed Web of Science ®Google Scholar
• Van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritisi for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516.
   PubMed Web of Science ®Google Scholar
• Winblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.
   PubMedGoogle Scholar
• Keysotne EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400–1411.
   PubMedGoogle Scholar
• Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66(6):732–739.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
   PubMed Web of Science ®Google Scholar
• Pelechas E, Voulgari PV, Drosos AA. ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2018;18(3):317–322.
   PubMed Web of Science ®Google Scholar
• Statista.com; [ cited 2020 Aug 26]. Available from: https://www.statista.com/statistics/318206/revenue-of-humira/
   Google Scholar
• Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889–894.
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Zikou AK, Voulgari PV, et al. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16:1–7.
   Web of Science ®Google Scholar
• Kaltsonoudis E, Pelechas E, Voulgari PV, et al. Neuroinflammatory events after anti-TNFα therapy. Ann Rheum Dis. 2020 May 20: annrheumdis-2020-217723. DOI:10.1136/annrheumdis-2020-217723
   PubMedGoogle Scholar
• Pelechas E, Papoudou-Bai A, Voulgari PV, et al. Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review. Rheumatol Int. 2019;39(2):353–357.
   PubMed Web of Science ®Google Scholar
• Pelechas E, Memi T, Markatseli TE, et al. Adalimumab-induced myasthenia gravis: case-based review. Rheumatol Int. 2020 Apr 22. DOI:10.1007/s00296-020-04587-4
   Web of Science ®Google Scholar
• Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005;4(4):637–641.
   PubMedGoogle Scholar
• Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004;10(4):333–338.
   PubMed Web of Science ®Google Scholar
• Beuthien W, Mellinghoff HU, Von Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004;50(5):1690–1692.
   PubMed Web of Science ®Google Scholar
• Toussirot E, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2:e000239.
   PubMed Web of Science ®Google Scholar
• Exarchou SA, Voulgari PV, Markatseli TE, et al. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol. 2009;38:328–331.
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat. 2004;15(5):280–294.
   PubMedGoogle Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355–363.
   PubMed Web of Science ®Google Scholar
• Pelechas E, Drosos AA. Etanercept biosimilar SB-4. Expert Opin Biol Ther. 2019;19(3):173–179.
   PubMed Web of Science ®Google Scholar
• Pelechas E, Voulgari PV, Drosos AA. Golimumab for rheumatoid arthritis. J Clin Med. 2019;8(3):387.
   Web of Science ®Google Scholar
• Bhalme M, Sharma A, Keld R, et al. PTU-107 weight adjusted anti-TNF therapy favours obese patients with Crohn’s disease. Gut. 2012;61:A228.
   Web of Science ®Google Scholar
• Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enrel): results form the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005;34(5):353–358.
   PubMed Web of Science ®Google Scholar
• Nikas SN, Voulgari PV, Alamanos Y, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis. 2006;65(2):257–260.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chadwick L, Mysler E, et al. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20:57.
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf. 2011;10(1):123–131.
   PubMed Web of Science ®Google Scholar
• Pelechas E, Voulgari PV, Drosos AA. Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2019;15:1073–1079.
   PubMed Web of Science ®Google Scholar
• Papagoras C, Drosos AA. Abatacept: a biologic immune modulator for rheumatoid arthritis. Expert Opin Biol Ther. 2011;11(8):1113–1119.
   PubMed Web of Science ®Google Scholar
• Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87–100.
   Web of Science ®Google Scholar
• Fleischmann R. A review of tofacitinib efficacy in rheumatoid arthritis patients who have an inadequate response or intolerance to methotrexate. Expert Opin Pharmacother. 2017;18(14):1525–1533.
   PubMed Web of Science ®Google Scholar
• Richez C, Truchetet ME, Kostine M, et al. Efficacy of baricitinib in the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2017;18(13):1399–1407.
   PubMed Web of Science ®Google Scholar
• Tarrant JM, Galien R, Li W, et al. Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b Trials. Rheumatol Ther. 2020;7(1):173–190.
   PubMed Web of Science ®Google Scholar
• Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(1):13–25.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–1800.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomized, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):P1541–1550.
   Google Scholar
• Voulgari PV, Drosos AA. Adalimumab in the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2014 Mar 4. DOI:10.1517/14712598.2014.894503
   PubMed Web of Science ®Google Scholar
• Voulgari PV, Kaltsonoudis E, Papagoras C, et al. Adalimumab in the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2012;12(12):1679–1686.
   PubMed Web of Science ®Google Scholar